Clinical Trials
91 trialsTNT Esophagus
Duke University
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
GRACIE
UNICANCER
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
PSI-Immune
University of Pittsburgh
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
SLURP
University Medical Center Groningen
OLIGOMETS
Yale University
Induction FLOT With CROSS CRT for Esophageal Cancer
University of Colorado, Denver
TNT-OES-2
Erasmus Medical Center
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
MEMENTO
Amsterdam UMC, location VUmc
ATTENUATION
Centre Leon Berard
ACROPOLI
SOLTI Breast Cancer Research Group
LOGICAN
UNICANCER
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
AuspiCiOus
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
RICE
University of Cologne
MiMe-A
Jules Bordet Institute
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
ICONIC
Royal Marsden NHS Foundation Trust
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
City of Hope Medical Center
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Columbia University
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Burzynski Research Institute
MATEO
AIO-Studien-gGmbH
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Translational Oncology Research International
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
PALAESTRA
Lund University Hospital
NeoRes
Karolinska University Hospital
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Case Comprehensive Cancer Center
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Academic and Community Cancer Research United
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Northwestern University
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Case Comprehensive Cancer Center